Learn More
5082 Background: In previous studies of patients (pts) with malignant ascites due to epithelial cancers, the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) demonstrated destruction of(More)
490 Background: In 2009 the trifunctional antibody catumaxomab was approved for the intraperitoneal (i.p.) treatment of malignant ascites (MA) in EpCAM-positive carcinomas in Europe. Overall survival(More)
TPS195 Background: Patients with epithelial ovarian cancer (OC) in 2nd or 3rd complete remission (CR) present with minimal residual disease that cannot be eliminated with standard chemotherapy and is(More)
  • 1